WHO Sounds Alert Over Critical Shortage of Weight-Loss Injections
Under a tenth of patients who could benefit from GLP-1 drugs like Wegovy can access them, states the global health agency as it releases its inaugural advice on the medications.
With more than one billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments.
According to estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"The latest guidance affirms that obesity is a long-term condition that can be treated with holistic and continuous support," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant obstacles to widespread availability to the jabs that can assist patients in reducing substantial body mass, explains the agency.
Skinny Jab Supply Crisis
Even in the present most favorable case, the manufacturing of such drugs could only cover about 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The advice calls on nations and manufacturers to increase access, via approaches like licensing agreements.
Exclusive production rights on a key compound – the main component of a leading brand – is due to expire in multiple countries in 2026.
How Weight-Loss Jabs Operate
The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost satiety so individuals eat less.
People commonly begin shedding pounds after several weeks of starting on the regular doses.
Research indicates people may see weight return after a year of discontinuing the drug, because their normal hunger come back.
Being carrying excess weight raises your chance for experiencing diseases, such as diabetes, heart disease, brain attack, and specific cancers.
Excess weight impacts people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
